-+ 0.00%
-+ 0.00%
-+ 0.00%
Davide Campari-Milano (BIT:CPR) Nine Month Update Puts Fair Value Back In Focus
Share
Listen to the news

Why the latest nine month update matters for Davide Campari-Milano

Davide Campari-Milano (BIT:CPR) stepped into focus after its nine months 2026 sales and trading statement call on 28 October, giving investors fresh information on how the beverage group is tracking this year.

The update landed with the stock at €6.24, alongside a one year total return of 4.96% and a past 3 months gain of 5.73%. This helps frame how the market has treated the story ahead of this latest disclosure.

The nine month update lands after a mixed stretch for Davide Campari-Milano, with a 13.21% year to date share price return set against a three year total shareholder return that declined 40.18%. This suggests recent momentum has improved even as longer term holders remain in the red.

The 1 day share price gain of 1.83% and 30 day share price return of 3.35% point to investors reacting positively around the latest sales and trading statement. However, the 7 day share price return that fell 7.01% shows sentiment had cooled ahead of the call, hinting that the new disclosure may be reshaping views on growth prospects and perceived risk.

Spot emerging momentum shifts around Davide Campari-Milano by comparing it with our hand picked 204 high quality undervalued stocks that share solid cash flows and balance sheet strength.

Bulls point to Davide Campari-Milano’s recent share price rebound and growing earnings, while bears focus on weak multi year returns and a low value score. Which side does the current valuation actually support?

Most Popular Narrative: 4% Overvalued

On the most followed narrative, Davide Campari-Milano screens as modestly overvalued, with a fair value of €5.99 against the latest close at €6.24. That small gap puts the share price slightly above what the narrative views as reasonable, which shapes how short term trading setups are framed.

This is a check on Campari on my Investing Portfolio watchlist, not a current position. Price €5.77 vs fair value €5.99 (about 3.8% discount to fair value). Narrow moat. Gross yield ~1.8%. Buy status: Good.

See why 1 investors see Davide Campari-Milano as 4% overvalued.

Result: Fair Value of €5.99 (OVERVALUED)

Still, the Davide Campari-Milano story could change quickly if weaker quarters return or if that long trading range around €5.10 to €6.75 breaks decisively.

Find out about the key risks to this Davide Campari-Milano narrative.

Another View: Davide Campari-Milano Through Cash Flows

The first narrative tagged Davide Campari-Milano as about 4% overvalued at €6.24 versus a €5.99 fair value. Our DCF model points the other way. On that approach, the shares trade around 13% below an estimated future cash flow value of €7.17, which frames the same price as a potential discount. Which lens do you trust more when those signals clash?

Look into how the SWS DCF model arrives at its fair value.

CPR Discounted Cash Flow as at Nov 2026
CPR Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Davide Campari-Milano for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 204 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on valuation and sentiment can be useful if you treat them as a prompt rather than a verdict. Move quickly and test the story against the data yourself with 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Davide Campari-Milano?

If Davide Campari-Milano has you thinking harder about price, quality, and risk, you can broaden your watchlist with a few targeted screens that surface specific traits quickly.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending